Treatment of bladder cancer with Bi-213-anti-EGFR-MAb – a pilot study
Following transurethral resection of non-muscle-invasive bladder cancer (carcinoma in situ) and subsequent chemotherapy and treatment with Bacillus Calmette–Guérin (BCG), up to 40% of patients relapse within 5 years. Therefore, new therapeutic strategies to combat tumor recurrence are needed. Because treatment of mice bearing intravesical human bladder cancer xenografts with Bi-213-anti-EGFR-MAb turned out highly efficient, the aim of this pilot study was to evaluate therapeutic efficacy of the α-emitter radioimmunoconjugate in bladder cancer patients.
SCHEIDHAUER Klemens;
SEIDL C.;
MORGENSTERN Alfred;
BRUCHERTSEIFER Frank;
APOSTOLIDIS Christos;
AUTENRIETH Michael;
KURTZ F;
ESSLER M.;
SCHWAIGER M.;
SENEKOWITSCH-SCHMIDTKE R.;
2014-08-01
SOC NUCLEAR MEDICINE INC
JRC88670
0161-5505,
Additional supporting files
| File name | Description | File type | |
|---|
